Cerebral venous thromboembolism in antiphospholipid syndrome successfully treated with the combined use of an anti-Xa inhibitor and corticosteroid

Internal Medicine

Volumn 54, Issue 23, 2015, Pages 3051-3056

  Sugie, Masayuki ^a,b   Iizuka, Natsuko ^a   Shimizu, Yuki ^a   Ichikawa, Hiroo ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b Endoscopic Center   (Japan)

Author keywords

Anti Xa inhibitor; Antiphospholipid syndrome; Cerebral venous sinus thrombosis; Corticosteroid

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; C REACTIVE PROTEIN; GLYCEROL; HEMOGLOBIN A1C; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RIVAROXABAN; TRYPTAMINE; VALPROIC ACID; WARFARIN; ANTICOAGULANT AGENT; CORTICOSTEROID;

ABDUCENS NERVE PARALYSIS; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CEREBROSPINAL FLUID; DIABETES MELLITUS; DRUG SUBSTITUTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEADACHE; HUMAN; HYPERCOAGULABILITY; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLEDEMA; PARTIAL THROMBOPLASTIN TIME; VISUAL IMPAIRMENT; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; COMPLICATION; MALE; MIDDLE AGED; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADRENAL CORTEX HORMONES; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DRUG THERAPY, COMBINATION; FACTOR XA INHIBITORS; HUMANS; MALE; MIDDLE AGED; RIVAROXABAN; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84948983807     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.5045     Document Type: Article

References (20)

1. Okuma H, Kitagawa Y. Diagnosis and potential treatment of antiphospholipid syndrome-related mainly on ischemic stroke. BrainNerve 65: 1319-1332, 2013 (in Japanese, Abstract in English).
2. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipidsyndrome: the new anticoagulants. Lupus 19: 486-491, 2010.
3. Sacco RL, Adams R, Albers G, et al. Guideline for prevention of stroke in patient with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/America Stroke Association Council in Stroke. Stroke 37: 577-617, 2011.
4. Ruiz-Irastorza G, Cuasdrado MJ, Ruiz-Arruza I, et al. Evidencebased recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20: 206-218, 2011.
5. The joint committee on guidelines for the management of stroke. Japanese guidelines for management of stroke 2009. Kyowa Kikaku, Tokyo, 2009: 99-100.
6. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499-2510, 2010.
7. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891, 2011.
8. Chighizola CB, Moia M, Meroni PL. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 23: 1279-1282, 2014.
9. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112: 947-950, 2014.
10. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 89: 1017, 2014.
11. Cohen H, Doré CJ, Clawson S, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) trial [Internet]. [ceted 2013 Feb 10]. Available from: http://isrctn.org/ISRCTN68222801
12. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827-1832, 2003.
13. Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev 13: 595-608, 2014.
14. Wendy L. Antiphospholipid syndrome. Hematology 10: 675-680, 2013.
15. Saadatnia M, Fatehi F, Basiri K, Mousavi SA, Mehr GK. Cerebral venous sinus thrombosis risk factors. Int J Stroke 4: 111-123, 2009.
16. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 118: 247-252, 2006.
17. Cervera R, Font J, Gómez-Puerta JA, et al. Validation of the pre liminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64: 1205-1209, 2005.
18. Gazioglu S, Solmaz D, Boz C. Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report. Hippokratia 17: 88-90, 2013.
19. Milhaud D, Heroum C, Charif M, Saulnier P, Pages M, Blard JM. Dural puncture and corticotherapy as risks factors for cerebral venous sinus thrombosis. Eur J Neurol 7: 123-124, 2000.
20. Gunal DI, Afsar N, Tuncer N, Aktan S. A case of multiple sclerosis with cerebral venous thrombosis: the role of lumbar puncture and high-dose steroids. Eur Neurol 47: 57-58, 2002.